[Breast carcinoma--adjuvant chemo- and hormone therapy]

Area of Science:

• Oncology
• Clinical Trials
• Evidence-Based Medicine

Context:

• Early breast cancer often involves occult micrometastases, leading to relapse despite local treatment.
• Pioneering work established the necessity of adjuvant systemic therapy for operable breast cancer.
• Prospective trials have largely confirmed the benefits of adjuvant systemic treatment.

Purpose:

• To review the evidence supporting adjuvant systemic treatment in early breast cancer.
• To discuss current treatment strategies for pre- and postmenopausal women.
• To highlight the importance of dose intensity and ongoing clinical trials.

Summary:

• Adjuvant systemic treatment improves disease-free and overall survival in early breast cancer.
• Treatment strategies vary by menopausal status, incorporating chemotherapy and hormonal manipulation.
• High-dose chemotherapy with stem cell rescue is under investigation but requires further evaluation.

Impact:

• Adjuvant systemic therapy is a cornerstone in improving outcomes for early breast cancer patients.
• Evidence-based medicine supports the continued use and refinement of these treatments.
• Encourages participation in clinical trials to advance breast cancer care.